Diagnosis of Periprosthetic Infection: Novel Developments.
Matsen Ko. Laura L; Parvizi. Javad J
Key Findings
- LL‑37 is highlighted as a promising biomarker for periprosthetic joint infection
- Other markers such as synovial CRP, α‑defensin, β‑defensin‑2/3, and leukocyte esterase are also discussed
- Current serum tests can be confused by other inflammatory conditions, so more specific markers are needed
Practical Outcomes
- For most biohackers, this research isn’t directly actionable because it focuses on diagnosing joint infections, not on everyday health or performance. However, it shows that LL‑37 can be a useful diagnostic tool in clinical settings, which might influence future medical tests if you ever need joint surgery.
Summary
The study looks at new ways to spot infections around joint implants, like hip or knee replacements. It says a protein called LL‑37, along with a few other markers, might help doctors tell if an infection is present more accurately than current blood tests.
Abstract
The diagnosis of periprosthetic joint infection (PJI) has been performed by obtaining a history and physical examination, blood tests, and analysis of the synovial fluid and tissue samples. The measurement of serum biomarkers are routinely used to diagnose PJI. These markers may be elevated in other inflammatory conditions, necessitating the need for more specific biomarkers to diagnose PJI. Serum biomarkers may be more specific to PJI. Synovial CRP, α-defensin, human β-defensin-2 and -3, leukocyte esterase, and cathelicidin LL-37 biomarkers hold promise for the diagnosis of PJI.
Study Information
pubmed
2016
10.1016/j.ocl.2015.08.003
38
70